Following incubation with fluorescently labeled SERT, Vilazodone had a KD in Na+ of 1.0 [0.4; 2.3] nM. In HEK293 cells treated at 5 μM for 16 h, Vilazodone produced significantly higher toxicity than vehicle treatment, while cell death did not exceed 50%. In intact COS-7 cells transiently expressing SERT WT, Vilazodone inhibited [3H]5-HT transport with an IC50 around 1 nM. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Vilazodone Affinity for Purified SERT
Cell-based study · fluorescently labeled SERT [1]
Fluorescently labeled SERT was incubated with Vilazodone for 2 h at RT. The KD for Vilazodone in Na+ was 1.0 [0.4; 2.3] nM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 16 serial-dilution concentrations from 0.012 nM to 400 nM
- Exposure duration
- 2 h at RT
- Method
- incubated
- Vehicle
- 20 mM HEPES, 0.05% GDN, 0.4% DMSO, and 150 mM NaCl
Methods and source locations
Compound reported in the paper: Vilazodone
The paper names Vilazodone without stating the salt or form; not verified as the hydrochloride form supplied as A11604. No dose conversion or lot validation.
Results > SERT binds vilazodone Na+-independently with nM affinity (S70, S73, S74); Methods > Fluorescence spectral shift binding experiments (S217, S222, S223, S227); Fig. 5 legend (S289)
vilazodone affinity for purified SERT: vilazodone affinity for purified SERT; comparator: target alone — Results > SERT binds vilazodone Na+-independently with nM affinity (S70, S74)
Vilazodone Toxicity in HEK293 Cells
Cell-based study · HEK293 cells [2]
HEK293 cells were treated with Vilazodone at 5 μM for 16 h. Toxicity was significantly higher than in vehicle-treated cells, while cell death did not exceed 50%.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 16 h treatment
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Vilazodone
The paper names Vilazodone without stating the salt or form; not verified as the hydrochloride form supplied as A11604. No dose conversion or lot validation.
Results > PPI Modulatory Activity of the FDA-Approved Drugs (S53); 6 legend (S339, S341)
percentage of pyknotic nuclei per field: percentage of pyknotic nuclei per field; comparator: vehicle-treated cells — Results > PPI Modulatory Activity of the FDA-Approved Drugs (S53); 6 legend (S339)
Vilazodone Inhibition of SERT WT Transport
Cell-based study · intact COS-7 cells transiently expressing SERT WT [1]
Vilazodone was added to intact COS-7 cells transiently expressing SERT WT. It inhibited [3H]5-HT transport by SERT WT with an IC50 around 1 nM.
Literature-Reported Treatment Conditions
- Exposure duration
- 30 min prior to the addition of 50 µL 12.25 nM [3H]5-HT; 3 min of incubation
- Method
- added to cells
- Reported limits
- Not stated in the sentences used: dose, vehicle.
Methods and source locations
Compound reported in the paper: Vilazodone
The paper names Vilazodone without stating the salt or form; not verified as the hydrochloride form supplied as A11604. No dose conversion or lot validation.
Results > Mutations in the allosteric site do not decrease the inhibition potency of vilazodone (S8); Methods > [3H]5-HT uptake experiments (S146, S148, S151); Fig. 1 legend (S254)
[3H]5-HT transport: [3H]5-HT transport; comparator: WT in absence of inhibitor — Results > Mutations in the allosteric site do not decrease the inhibition potency of vilazodone (S8)